Browsing Category

42431 posts
"Human Creativity is Inspired by Abstract Connections That AI Cannot Intuitively Make"

"Human Creativity is Inspired by Abstract Connections That AI Cannot Intuitively Make"

The Orangeblowfish Creative Agency Founder to Join Dynamic Panel at Design Shanghai…

New Akamai Study Reveals API Security Incidents Cost APAC Enterprises Over US$580,000 on Average in the Past Year

Internal disconnects, poor visibility, and misaligned priorities leave organizations vulnerable to costly…

SGS & Co and SGK unite to become Propelis – a global agency built for brand impact

Propelis family of brands created to serve wide range of client needs…
Lake Resources Announces Exploration of Strategic Alternatives

Lake Resources Announces Exploration of Strategic Alternatives

SYDNEY, May 7, 2025 /PRNewswire/ — Lake Resources N.L. (ASX: LKE; OTC: LLKKF)…

FancyTech Closes Series B+ to Power AI Personalized Content Solutions in Thailand and Southeast Asia

BANGKOK, May 7, 2025 /PRNewswire/ — FancyTech, an AI startup specializing in…
Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.

Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.

AJICAP® Antibody-Drug Conjugate Manufacturing Technology Contributes to Enhanced Efficacy of Antibody Drugs…

Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema

SAN FRANCISCO and SUZHOU, China, May 7, 2025 /PRNewswire/ — Innovent Biologics,…

CStone Presents Preclinical Results of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR

SUZHOU, China, May 7, 2025 /PRNewswire/ — CStone Pharmaceuticals ("CStone", HKEX: 2616), an…